GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stereotaxis Inc (AMEX:STXS) » Definitions » 5-Year Yield-on-Cost %

Stereotaxis (Stereotaxis) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 28, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Stereotaxis 5-Year Yield-on-Cost %?

Stereotaxis's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for Stereotaxis's 5-Year Yield-on-Cost % or its related term are showing as below:



STXS's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.17
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Stereotaxis's 5-Year Yield-on-Cost %

For the Medical Instruments & Supplies subindustry, Stereotaxis's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stereotaxis's 5-Year Yield-on-Cost % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stereotaxis's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Stereotaxis's 5-Year Yield-on-Cost % falls into.



Stereotaxis 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Stereotaxis is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Stereotaxis  (AMEX:STXS) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Stereotaxis 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Stereotaxis's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Stereotaxis (Stereotaxis) Business Description

Traded in Other Exchanges
Address
710 North Tucker Boulevard, Suite 110, St. Louis, MO, USA, 63101
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.
Executives
Paul J Isaac 10 percent owner 530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Myriam Curet director 1020 KIFER ROAD, SUNNYVALE CA 94086
David Benfer director 5 SELDEN AVENUE, BRANFORD CT 06404
Kimberly R. Peery officer: Chief Financial Officer C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE: SUITE 100, ST. LOUIS MO 63108
Kevin M. Barry officer: Chief Legal Officer & Secretar 4320 FOREST PARK AVENUE, 100, ST. LOUIS MO 63108
Ross B Levin director 530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Fariba Fischel Ghodsian 10 percent owner 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Dafna Capital Management Llc 10 percent owner 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
David Leo Fischel director 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Arun Swarup Menawat director 2412 EIGHTH LINE, OAKVILLE A6 L6H6S9
Joe E Kiani director 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Paul Brathwaite officer: VP Research & Development C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Martin C Stammer officer: Chief Financial Officer C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Nathan Fischel director 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Duane Desisto director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730

Stereotaxis (Stereotaxis) Headlines